Healthy individuals (Intended indications and effects: Improvement of skin barrier function)
Conditions
Interventions
Test food: Ginger extract powder
Duration: 12 weeks
Administration: Consume one capsule per day in the morning.
Test food: Dextrin
Duration: 12 weeks
Administration: Consume one capsule per day in th
Sponsors
Izumi Tatsuya
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Japanese 2. Women 3. Individuals aged between 25 and 40 4. Healthy individuals 5. Individuals whose transepidermal water loss (TEWL) is high at screening
Exclusion criteria
Exclusion criteria: 1. Individuals who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, or myocardial infarction 2. Individuals who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Individuals who are taking "Foods for Specified Health Uses" or "Foods with Functional Claims" 5. Individuals who are taking or using medications (including herbal medicines) or supplements 6. Individuals who have been diagnosed with atopic dermatitis 7. Individuals who use any products except for cosmetic creams, beauty essence, all-in-one cosmetic makeup, skin lotions such as face masks, milky lotions, and sunscreen for daily skincare 8. Individuals who habitually receive skincare treatment (e.g., aesthetic treatment) or use instruments for beauty treatment (e.g., facial treatment device) 9. Individuals who have undergone cosmetic surgery 10. Individuals who are allergic to medicines or foods related to the test product (particularly, ginger) 11. Individuals who are pregnant, lactating, or planning to become pregnant during this study 12. Individuals who have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate in another study during this study 13. Individuals who are judged as ineligible to participate in this study by the physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. The measured value of TEWL at 12 weeks after intervention (12w) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The measured value of the moisture content of skin surface at 12w 2. The measured values of viscoelasticity of skin (R0~R9) at 12w 3. The measured values of Intensity, Skin Thickness, and Low Echogenic Band (LEB) at 12w 4. The measured values of systolic and diastolic blood pressure at 12w | — |
Contacts
Public ContactNaoko Suzuki
ORTHOMEDICO Inc.
Outcome results
None listed